COVID-19 – Infection control advices

- Personal views
- Policies are guidelines
- Clinical practice
- Qualitative, not quantitative

Alin Bortan, MD Infectious Diseases Lawrence and Memorial Hospital New London, CT

Short concepts

- Sickness vs. carriage (portage)



Testing for viral load (PCR) is a surrogate for the diagnosis of the infection

Person-to-person is the primary mode of transmission



- Long range #3 (controversial): aerosolization
 - Transmission in enclosed poorly ventilated spaces (outbreaks associated with riding bus, sitting restaurant, standing hall)
 - Long range airborne transmission is possible, but not probable
 - airborne precautions are universally recommended when aerosolgenerating procedures are performed (close-range situations)

Non-respiratory specimens

- Uncertain role of transmission:
 - Stool: long time clearance RNA, occasionally (+) viral cultures
 - Blood
 - Ocular secretions
 - Semen
- Case reports aerosolization of virus from sewage drainage
- Overall fecal oral route not significant
- Unlike transmission through non-mucous membranes (abraded skin)

 Infectiousness started 2.3 days prior to symptom onset, peaked 0.7 days before symptom onset, and declined within seven days

Nat Med. 2020;26(5):672



Testing for Coronavirus



NY Times



Transmission <> Infectiousness

- Correlates with the inoculum size [RNA viral load]
- Begins before the development of symptoms
- Highest early in the course of illness
- Greatly diminishes during illness
- After 7-10 days transmission is unlikely*
 [*immunocompetent patients with nonsevere infection]
- Prolonged viral RNA detection ** does not necessarily indicate prolonged infectiousness
 - viral RNA shedding is variable
 - may increase with age and the severity of illness
 - [** severe or critical COVID-19 or in immunocompromised patients]

Concepts

- Asymptomatic transmission
- Superspreading events
- Highest transmission = prolonged contact + indoors/confined space
 - Household contacts
 - Health care settings before implementation of preventive measures
 - Congregate settings: cruise ships, homeless shelters, detention facilities, college dormitories, public transportation enclosures (subways, etc)
- Low risk of transmission with indirect contacts
 - passing by someone with infection on the street
 - Environmental contamination viral persistence varies



Post-disease immunity

- 1. HUMORAL = IgG SARS-CoV2 ANTIBODY production
 - ~ severity of disease
 - Uncertain duration of neutralizing activity
- 2. CELL-mediated
 - Immune competency
 - Life long

Is **re-infection** possible? *Sporadic cases of reinfections (vs. asymptomatic portage) have been documented*

- [animal models re-exposure to virus: protection does exist]
- after **infection**: lower RNA levels; more rapid clearance of viral RNA
- similar behavior post vaccination

Particular settings

- Animal contacts:
 - symptomatic felines, minks
 - (carriage dogs)
 - (Pigs and poultry not susceptible)

PERSONAL PREVENTION STRATEGIES

- Social distancing: minimizes close-contact range exposures
- Wearing masks* outside the household
 - (* all types OK)
 - (* avoid touching eyes, nose, mouth)
 - (* ~ avoid touching the mask)
 - (* launder cloth masks routinely)

(*social distancing + high adoption of mask-wearing by the general public = the most effective preventive modalities in my opinion)

- Hand washing after touching public/environment surfaces
- Respiratory etiquette
- Cleaning environment surfaces
- Ventilation of closed spaces

PUBLICH HEALTH STRATEGIES

- Community lockdown (vs universal lockdown??)
 - Stay-at-home orders
 - Closure of schools, venues and nonessential businesses
 - Bans on public gatherings
 - Travel restrictions
 - Aggressive case identification and isolation
 - Contact tracing and quarantine measures
 - social distancing + high adoption of mask-wearing by the general public
- Screening in congregate settings: Long term facilities, campuses
 ~ 0.2% rate of asymptomatic carriers June 2020 YNHH health care workers

Quarantine of 14 days

- Asymptomatic individuals with potential exposure
 - Daily monitoring for fever, cough, or dyspnea for 14 days
 - Testing 5-7 days after exposure, if possible
 - If positive (test, symptoms): stay at home quarantine x14 days +
 6 feet distance
- Shorter Quarantines:
 - 10-day quarantine if asymptomatic throughout
 - 7-day quarantine if asymptomatic + negative test by day 5

COVID-19 (+) patients in the community

- Home management is possible for most patients
 - Telemedicine
 - Symptom control
 - Hydration
 - PO steroids
 - Infection control at home: Isolation, minimal use of shared spaces, separate bathroom/bedroom, face mask, hand hygiene, disinfection* and disposal system)
 - * diluted household bleach, solutions with >70% alcohol
- Admission indicated for higher level of care
 - (high O2 requirements)
 - (fever, diarrhea)

Hospital prevention of transmission

- Room isolation of positive patients
 - private or cohorting in semi-private rooms
 - negative-pressure when available (esp. aerosolizing procedures)
- Restriction of visitors
- Universal nucleic acid testing (prior to elective procedures; upon admission)
- Use of personal protective equipment
 - Universal masking: patients, visitors and HCWs*
 - (*HCW should wear masks even when not on patient-duty)
 - Hand hygiene
 - Eye protection
 - (Hair covers, shoe covers)
- Enhanced environmental cleaning and disinfection protocols

Re-use of PPE (shortage)

- UV light
- H2O2 vapor
- Moist heat

(no makeup, no skin lotions, no beard oils, no write-on masks)

DISCONTINUATION OF PRECAUTIONS (1)

FACT persistent + SARS-CoV-2 PCR testing weeks - months after resolution of symptoms

OBS virus does not remain infectious after > 10 days from onset of illness [immunocompetent patients who have improved after nonsevere infection]

FACT the gold standard for determining infectivity is the viral culture (not routinely available)

 Patients should continue to follow public health recommendations in public settings (social distancing, face masks)

DISCONTINUATION OF PRECAUTIONS (2)

1. Non-test-based decisions

- Immunocompetent patients; mild/moderate disease
 - Symptom onset > 10 days **AND**
 - Resolution of fever > 24 hours prior (unmedicated) AND
 - Clinical improvement (eg, cough, shortness of breath)
- Immunosuppressed patients; severe COVID-19 disease
 - Symptom onset > 10 days (up to 20 day) AND
 - Resolution of fever > 24 hours prior (unmedicated) AND
 - Clinical improvement of symptoms (Cough, SOB)
- **2. Test based decisions** = considered more powerful (discharge to NH)
 - Two consecutive rapid tests for SARS-CoV-2 ≥24 hours apart
 - PCR re-testing 10 to 20 days after symptom onset to assess the Ct (Cycle Threshold)

Long term facilities

- symptom screening and universal use of masks upon entering the facility
- frequent PCR testing for HCWs and/or residents
- Steroid therapy is available for mild cases
- Symptom control is available for low Oxygen requirements
- No specific therapy is available (IV formulations)